Examples of using Centralised procedure in English and their translations into Bulgarian
{-}
-
Official
-
Colloquial
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The centralised procedure is compulsory for.
The framework of the centralised procedure.
The centralised procedure is compulsory for.
This reference product was approved through the centralised procedure and has been marketed in Europe since November 1995.
In the Centralised Procedure applications are submitted directly to the EMA.
In the EU, biosimilar medicines are approved via the European Medicines Agency's(EMA) centralised procedure.
Applications under the centralised procedure are made to the European Medicines Agency(EMA).
This guideline is applicable to medicinal products for human use authorised according to the Community centralised procedure.
Under the centralised procedure, pharmaceutical companies submit a single marketing-authorisation application to the EMA.
The number of generic medicinal products for which authorisation is being sought through the centralised procedure is growing.
Judgments of civil courts are enforceable through a centralised procedure administered by the Enforcement of Judgments Office.
The certificates confirm the marketing-authorisation status of products authorised through the centralised procedure.
The centralised procedure is compulsory for all medicinal products for human and animal use derived from biotechnology processes.
First, the replacement of the decentralised authorisation procedure with a centralised procedure at EU level.
The system for the centralised procedure is nearly complete, with adjustments for postauthorisation procedures being planned for early 2007.
In line with the legislation, development will focus on products authorised using the centralised procedure in this first phase.
Optional access to the centralised procedure should be maintained for veterinary medicinal products containing a new active substance.
It also emerges from the report that the general principles previously established which govern the centralised procedure should be maintained.
The use of the centralised procedure should be encouraged in every way, in particular by facilitating access for small and medium-sized enterprises(SMEs).
The Commission and the Agency shall develop andencourage use of the centralised procedure, particularly by facilitating access for SMEs.
If one or more Member States or the Agency do not agree to a draft decision,it should be made subject to a centralised procedure.
The authorisation of a medicine under the centralised procedure is a two-stage process, involving the European Medicines Agency(EMA) and the European Commission.
Each EU Member State has its own procedures for the authorisation of medicines that fall outside the scope of the centralised procedure.
The centralised procedure allows the marketing of a medicine on the basis of a single EU-wide assessment and marketing authorisation which is valid throughout the EU.
The Agency's evaluations of marketing-authorisation applications submitted through the centralised procedure provide the basis for the authorisation of medicines in Europe.
All medicinal products for human and animal use derived from biotechnology andother high-technology processes must be approved via the centralised procedure.
In 2008, the scope of the mandatory centralised procedure will extend to products for autoimmune diseases and other immune dysfunctions and viral diseases.
Providing a single route for the evaluation of innovative medicines in the EU,hereby avoiding the duplication of the evaluation in Member States(centralised procedure).
(6c) In the interest of public health, authorisation decisions adopted under the centralised procedure should be taken on the basis of the objective scientific criteria of quality, safety and efficacy.
The EMA is responsible for the scientific evaluation of applications for European marketing authorisation for medicinal products(centralised procedure).